Pharmacologic Augmentation of TMS for Depression With D-serine
ConditionDepression
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-80
SponsorMclean Hospital
About this trial
The goal of this study is to test whether combining D-serine with 30 treatments of a) iTBS and b) 18-Hz protocols will enhance clinical outcomes compared to rTMS with placebo (i.e., sugar pill). The investigators hypothesize that NMDA receptor activation via D-serine combined with repeated sessions of rTMS will produce greater clinical outcomes than iTBS with placebo and 18-Hz with placebo.
Eligibility criteria
Qualifiers
Clinical diagnosis of MDD
English-speaking
Adults aged 18-80
Must be able to swallow capsules
Disqualifiers
Containing any implanted metal or devices
Current or previous seizure history
Active substance use that may significantly alter the seizure threshold
Patients with pre-existing renal disease
Trial design
Treatments tested in this trial
- TMS
- D-serine
- Placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov